SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genaissance Pharmaceuticals (GNSC)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who started this subject3/25/2003 8:55:28 AM
From: nigel bates   of 183
 
NEW HAVEN, Conn., March 25 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has signed an agreement with Wayne State University (WSU) to support WSU's research contract with the National Institute of Child Health and Human Development's Perinatology Research Branch (PRB), which is located at the WSU School of Medicine in Detroit, Michigan. Under the agreement, WSU will gain access to specific HAP (TM) Markers and obtain a limited license to use the Company's DecoGen (R) Informatics System. Genaissance will develop assays for the selected HAP (TM) Markers and provide high-throughput genotyping on clinical samples provided by WSU and the PRB. Genaissance will receive a license fee and other payments from WSU.

"We are delighted to enter into an agreement with WSU, which is working with the PRB to address important healthcare issues of adverse pregnancy outcomes," said Gerald F. Vovis, Ph.D., Executive Vice President and Chief Technology Officer of Genaissance Pharmaceuticals. "This is our first major agreement in the public sector and reinforces the utility of our HAP (TM) Technology for helping to detect associations between clinical outcomes and genetic variation."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext